iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Piramal Pops on US Zinc Injection Launch

17 Jan 2024 , 10:47 AM

Following the announcement by its Piramal Critical Care (PCC) business on the introduction of zinc sulphate injection in the US, shares of Piramal Pharma Limited saw an increase of more than one percent, closing at Rs 140 in early trade on January 17.

In an exchange statement on January 16, the business stated, ‘The launch will enable PCC further to expand their existing Zinc Sulphate Injection product line and overall the generic injectables portfolio.’

The share was down 0.5% from the previous closing at Rs 137.5 on the National Stock Exchange at 10:51 am. Over the last year, the stock has increased by almost 24%.

When oral or enteral nutrition is not feasible, insufficient, or inappropriate, zinc sulphate is recommended as a trace element for zinc nutrition in both adult and pediatric patients.

Zinc Sulphate for Injection, USP 10mg/10ml is the most recent medication to be introduced into the generic injectables market by Piramal Critical Care.

The business expanded its wide range of critical care medicines in 2023 with the introduction of Doxycycline for Injection, USP, and Pantoprazole Sodium for Injection, USP.

Peter DeYoung, CEO of Piramal Global Pharma, stated, ‘The introduction of Zinc Sulphate Injection expands our US portfolio of injectable products, complementing our inhaled anesthesia offerings.’

For feedback and suggestions, write to us at editorial@iifl.com

 

Related Tags

  • Pharma
  • Piramal
  • Zinc Injection
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.